Science Publications

Sign Up
Sign In
Submit
Current Research in Public Health
Cite This Article Share Download PDF XML
  1. Home
  2. Journals
  3. Current Research in Public Health
  4. Archive
  5. Volume 3, Issue 1, 2023
  6. Article
Case Report Open Access October 13, 2023

A Report of Three Cases with Moderate Psoriasis Treated with New Topical Treatment

José Miguel Ingelmo Calvo 1, José Ruiz Cobo 2 and Mohamed Farouk Allam 3,*
1
Department of Plastic Surgery, Hospital HM Malaga, Malaga, Spain
2
Distrito Sanitario Costa del Sol, SUAP Torremolinos, Malaga, Spain
3
Department of Family Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Publihed in: Current Research in Public Health (Volume 3, Issue 1, 2023)
Page(s): 16-20
DOI: 10.31586/gjmcr.2023.714
Received
June 25, 2023
Revised
August 30, 2023
Accepted
October 11, 2023
Published
October 13, 2023
Keywords
Psoriasis; Topical Treatment; Psoriasis Area Severity Index; Case Report; Malaga
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright: Copyright © The Author(s), 2023. Published by Scientific Publications
Article metrics
Views
1013
Downloads
170

Cite This Article

APA Style
Calvo, J. M. I. , Cobo, J. R. , & Allam, M. F. (2023). A Report of Three Cases with Moderate Psoriasis Treated with New Topical Treatment. Current Research in Public Health, 3(1), 16-20. https://doi.org/10.31586/gjmcr.2023.714
ACS Style
Calvo, J. M. I. ; Cobo, J. R. ; Allam, M. F. A Report of Three Cases with Moderate Psoriasis Treated with New Topical Treatment. Current Research in Public Health 2023 3(1), 16-20. https://doi.org/10.31586/gjmcr.2023.714
Chicago/Turabian Style
Calvo, José Miguel Ingelmo, José Ruiz Cobo, and Mohamed Farouk Allam. 2023. "A Report of Three Cases with Moderate Psoriasis Treated with New Topical Treatment". Current Research in Public Health 3, no. 1: 16-20. https://doi.org/10.31586/gjmcr.2023.714
AMA Style
Calvo JMI, Cobo JR, Allam MF. A Report of Three Cases with Moderate Psoriasis Treated with New Topical Treatment. Current Research in Public Health. 2023; 3(1):16-20. https://doi.org/10.31586/gjmcr.2023.714 
@Article{crph714,
AUTHOR = {Calvo, José Miguel Ingelmo and Cobo, José Ruiz and Allam, Mohamed Farouk},
TITLE = {A Report of Three Cases with Moderate Psoriasis Treated with New Topical Treatment},
JOURNAL = {Current Research in Public Health},
VOLUME = {3},
YEAR = {2023},
NUMBER = {1},
PAGES = {16-20},
URL = {https://www.scipublications.com/journal/index.php/GJMCR/article/view/714},
ISSN = {2831-5162},
DOI = {10.31586/gjmcr.2023.714},
ABSTRACT = {Practice guidelines recommend fixed combinations of calcipotriol, a topical vitamin D analogue, and betamethasone dipropionate, a high potency corticosteroid, as first line topical treatment for mild to moderate plaque psoriasis of the body and scalp. A new foaming lotion for treatment of Psoriasis was developed and patented by the Spanish Ministry of Industry, Trade and Tourism (Invention patent reference number 202030824). The foaming lotion is composed of clobetasol, papaverine hydrochloride, spironolactone, milk-peptide-complex and propylene glycol. Three cases with moderate Psoriasis aged 34, 36 and 66 years old were treated with our new foaming lotion for 7-8 days. The three patients reported important improvement in the itching sensations and remission of the scaled lesions. Before and after application of the new foaming lotion, Psoriasis Area Severity Index (PASI) scores improved in the first patient from 24.3 to 1.8, in the second patient from 26.1 to 1.8, and in the third patient from 27 to 1.8. Our results show the short-term effectiveness of the new foaming lotion in treating moderate and extensive Psoriasis. Long follow-up is needed to evaluate the remission period of Psoriasis and possible side effects of the new topical treatment.},
}
%0 Journal Article
%A Calvo, José Miguel Ingelmo
%A Cobo, José Ruiz
%A Allam, Mohamed Farouk
%D 2023
%J Current Research in Public Health

%@ 2831-5162
%V 3
%N 1
%P 16-20

%T A Report of Three Cases with Moderate Psoriasis Treated with New Topical Treatment
%M doi:10.31586/gjmcr.2023.714
%U https://www.scipublications.com/journal/index.php/GJMCR/article/view/714

TY  - JOUR
AU  - Calvo, José Miguel Ingelmo
AU  - Cobo, José Ruiz
AU  - Allam, Mohamed Farouk
TI  - A Report of Three Cases with Moderate Psoriasis Treated with New Topical Treatment
T2  - Current Research in Public Health
PY  - 2023
VL  - 3
IS  - 1
SN  - 2831-5162
SP  - 16
EP  - 20
UR  - https://www.scipublications.com/journal/index.php/GJMCR/article/view/714
AB  - Practice guidelines recommend fixed combinations of calcipotriol, a topical vitamin D analogue, and betamethasone dipropionate, a high potency corticosteroid, as first line topical treatment for mild to moderate plaque psoriasis of the body and scalp. A new foaming lotion for treatment of Psoriasis was developed and patented by the Spanish Ministry of Industry, Trade and Tourism (Invention patent reference number 202030824). The foaming lotion is composed of clobetasol, papaverine hydrochloride, spironolactone, milk-peptide-complex and propylene glycol. Three cases with moderate Psoriasis aged 34, 36 and 66 years old were treated with our new foaming lotion for 7-8 days. The three patients reported important improvement in the itching sensations and remission of the scaled lesions. Before and after application of the new foaming lotion, Psoriasis Area Severity Index (PASI) scores improved in the first patient from 24.3 to 1.8, in the second patient from 26.1 to 1.8, and in the third patient from 27 to 1.8. Our results show the short-term effectiveness of the new foaming lotion in treating moderate and extensive Psoriasis. Long follow-up is needed to evaluate the remission period of Psoriasis and possible side effects of the new topical treatment.
DO  - A Report of Three Cases with Moderate Psoriasis Treated with New Topical Treatment
TI  - 10.31586/gjmcr.2023.714
ER  -